## 5 Conclusions
\begin{tabular}{p{113.8 pt} p{113.8 pt} p{113.8 pt}} \hline
**Title** & **Type of Study/Sample** & **Conclusions** \\ \hline Clarifying the link between cannabis use and risk of psychosis. [23] & Narrative & The onset of psychotic disorder is higher in cannabis users. Gene variations such as AKT1 increase the risk of developing psychosis. \\ \hline The AKT1 genotype moderates the acute psychotomimetic effects of naturally smoked cannabis in young cannabis smokers. [34] & Psychotic symptoms were increased in cannabis-intoxicated individuals who had the variation in the rs2494732 locus of the AKT1 gene increasing with the dose of the C allele. In addition, these symptoms may be exacerbated because THC increases dopamine, the main neuromediator involved in the positive symptoms of psychosis. Unlike the AKT1 locus he rs2494732, the COMT Val/ Met genotypes do not mediate the acute psychotic response to cannabis from cannabis use. \\ \hline Laboratory study in humans on cannabis and psychosis. [29] & Narrative \\ \hline Cannabis and psychosis: How much proof do we require? [42] & Narrative & The probability of risk of psychotic disorder is greater in cannabis users with genetic polymorphism of AKT1 rs2494732 loci of the C allele is associated with schizophrenia in cannabis users. In addition, cannabis produces an increased risk of psychotic disorder when the Val allele is present in the COMT gene. \\ \hline Cannabis and psychosis: How much proof do we require? [42] & Narrative & There is a significant association between cannabis use and psychotic experiences in carriers of variants in the AKT1 gene. In addition, a variation of DRD2 increases the risk of psychosis in cannabis users. \\ \hline GABA deficiencies increase the psychotomimetic effects of \(\Delta\)9-THC. [44] & Cases and controls/ N = 27 & The variation in the AKT1 gene increases the risk of psychosis in cannabis users since it interacts with the neurophysiological response to THC. \\ \hline Interaction between genetic variations of DRD2 and AKT1 in the risk of psychosis in cannabis users: a case-control study. [18] & Cannabis users who are carriers of the AKT1 gene with the rs2494732 locus have a higher probability of psychosis; however, the risk is higher in those with the C/C genotype. High mesolimbic dopamine levels make a person with the AKT1 gene polymorphism more vulnerable to the psychotic effects of THC use. \\ \hline Cannabis and psychosis. [31] & Narrative & Cannabis users with the C/C allele in AKT1 are at increased risk of psychosis. The interaction of variations in the AKT1 and DAT1 genes produces greater sensitivity to the psychotomimetic effects of THC. There is no interaction between the COMT genetic polymorphism and cannabis use for schizophrenia. There is a greater release of dopamine mediated by CB-1 receptors due to THC in people with a first-degree family history. \\ \hline Genotype-based prevention of the onset of psychosis and schizophrenia: a personalized approach in a target population. [26] & Narrative \\ \hline \end{tabular}  The AKT1 rs2494732 SNP confers greater vulnerability to psychosis in cannabis users. There is an increased risk of psychosis in people with the C/C genotype at AKT1 rs2494732 compared to those with the T/T genotype.